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Abstract
Background: To the best of our knowledge, data on effects of probiotic administration on hormonal profiles, biomarkers of 
inflammation and oxidative stress in women with polycystic ovary syndrome (PCOS) are scarce.  This investigation was conducted 
to assess the effects of probiotic supplementation on hormonal profiles, biomarkers of inflammation and oxidative stress in women 
with PCOS. 
Methods: This randomized, double-blind, placebo-controlled trial was conducted on 60 women with PCOS, aged 18-40 years 
old. Subjects were randomly assigned into 2 groups to receive either probiotics or placebo (n = 30 each group) for 12 weeks. 
Metabolic profiles were quantified at baseline and after a 12-week intervention. 
Results: After the 12-week intervention, compared with placebo, probiotic supplementation significantly increased serum sex 
hormone-binding globulin (SHBG) (+25.9 ± 32.5 vs. +0.5 ± 15.6 nmol/L, P < 0.001) and plasma total antioxidant capacity (TAC) 
(+8.8 ± 120.5 vs. -98.3 ± 246.4 mmol/L, P = 0.04), and significantly decreased serum total testosterone (-0.2 ± 0.7 vs. +0.2 ± 0.6 
ng/mL, P = 0.03), modified Ferriman-Gallwey (mF-G) scores (-1.7 ± 1.5 vs. -0.2 ± 1.0, P < 0.001), serum high-sensitivity C-reactive 
protein (hs-CRP) (-1150.0 ± 1295.2 vs. +202.5 ± 1426.3 ng/mL, P < 0.001) and plasma malondialdehyde (MDA) concentrations 
(-0.2 ± 0.6 vs. +0.9 ± 1.3 µmol/L, P < 0.001). We did not observe any detrimental effect of probiotic supplementation on other 
metabolic profiles. 
Conclusion: Overall, probiotic supplementation of PCOS women for 12 weeks had beneficial effects on total testosterone, SHBG, 
mFG scores, hs-CRP, TAC and MDA levels but did not affect other metabolic profiles. 
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Introduction
Polycystic ovary syndrome (PCOS) is an endocrine 
disorder in reproductive years affecting 5%–10% of 
premenopausal women.1 Subjects with PCOS frequently 
have metabolic disorders including cardiovascular disease 
(CVD), type 2 diabetes mellitus (T2DM), dyslipidemia, 
insulin resistance, hyperandrogenemia, visceral obesity 
and endothelial dysfunction.2,3 Low-grade inflammation 
can induce production of  inflammatory factors in PCOS 
as well as directly stimulate excess ovarian androgen 
production, which in turn would result in increased 
oxidative stress.4
Nowadays, there is a growing interest to use probiotics 
in patients with metabolic diseases such as T2DM.5 The 
basis of  this interest derives mainly from the results 
of  studies suggesting that dysbiosis of  gut microbiota 
has been implicated in multiple disease states such as 
diabetes, obesity and CVD.6,7 Few studies have evaluated 
the effects of  probiotic supplementation on metabolic 
profiles in PCOS women. In a study by Guo et al,8 it was 
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observed that dysbiosis of  gut microbiota correlated with 
pathogenesis of  PCOS and microbiota interventions 
through microbiota transplantation and Lactobacillus 
transplantation were effective for treatment of  PCOS 
rats. We have previously shown that taking probiotic 
supplements for 12 weeks by PCOS women had favorable 
effects on markers of  insulin metabolism, triglycerides 
and VLDL-cholesterol values, but did not affect other 
lipid profiles.9 In addition, probiotic supplementation for 
6 months could serve as a novel therapeutic option in the 
clinical management of  knee osteoarthritis likely through 
reducing high sensitivity C-reactive protein (hs-CRP) 
concentrations.10 Probiotic soy milk administration for 8 
weeks to diabetic kidney disease patients could improve 
few biomarkers of  oxidative stress.11 
This evidence suggests the importance of  probiotic 
supplementation for patients with PCOS. Probiotic 
intake may affect metabolic profiles, biomarkers of 
inflammation and oxidative stress through production 
of  short chain fatty acid (SCFA), decreased expression 
of  inflammation-relevant genes,12 and up-regulation 
of  oxidative pentose pathway activity.13 To the best 
of  our knowledge, data on the effects of  probiotic 
supplementation on hormonal profiles, biomarkers of 
inflammation and oxidative stress in women with PCOS 
are limited. The objective of  this study was to evaluate 
the effects of  probiotic supplementation on hormonal 
profiles, biomarkers of  inflammation and oxidative stress 
in these patients.
Subjects and Methods
Trial Design and Participants 
This randomized, double-blind, placebo-controlled 
clinical trial, registered in the Iranian registry of  clinical 
trials (identifier: IRCT201704235623N112, http://www.
irct.ir), conducted at a Akbarabadi clinic affiliated to 
Iran University of  Medical Sciences (IUMS), Tehran, 
Iran, among 60 women with PCOS, aged 18–40 years 
old between January 2017 and August 2017. This 
investigation was conducted in accordance with the 
Declaration of  Helsinki and informed consent form was 
taken from all individuals. The research was approved 
by the ethics committee of  IUMS. Diagnosis of  PCOS 
was carried out according to the Rotterdam criteria.14 
Biochemical hyperandrogenism defined based on total 
testosterone levels >2 nmol/L. Exclusion criteria were as 
follows: smokers, taking probiotic supplements, pregnant 
women, endocrine diseases including thyroid, diabetes 
and/or impaired glucose tolerance. 
Study Design
At first, all subjects were randomly divided into 2 groups 
to receive either probiotic supplements containing 
Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium 
bifidum (2 × 109 CFU/g each) or placebo (starch) (n = 30 
each group) for 12 weeks. The appearance of  the placebo 
was similar in color, shape, size, and packaging, smell 
and taste from the probiotic capsule. All capsules were 
produced by Tak Gen Zist Pharmaceutical Company 
(Tehran, Iran). All patients completed 3-day food records 
and three physical activity records as metabolic equivalents 
(METs) at weeks 0, 3, 6, 9, and 12 of  the intervention. 
Daily macro- and micro-nutrient intakes were analyzed 
by nutritionist IV software (First Databank, San Bruno, 
CA) adapted for the Iranian food pattern.15 
Treatment Adherence
To evaluate the compliance the remaining supplements 
were counted and subtracted from the amount of 
supplements provided to the individuals. To increase 
compliance, all individuals received short messages on 
their cell phones every day to remind them about taking 
the capsules.
Clinical Assessments
Clinical assessments included determinations of 
hirsutism using a mFG scoring system,16 of  acne score17 
and of  alopecia based on assessment guidelines collated 
by Olsen et al.18
Assessment of  Outcomes
Hs-CRP was considered as the primary outcomes, 
and nitric oxide (NO), biomarkers of  oxidative stress 
and hormonal profiles were defined as the secondary 
outcomes. Ten milliliters fasting blood samples were 
collected at baseline and after the 12-week treatment at 
Akbarabadi reference laboratory, Tehran, Iran. Serum 
total testosterone with inter- and intra-assay coefficient 
variances (CVs) of  4.1 to 6.0%, sex hormone-binding 
globulin (SHBG) with inter- and intra-assay CVs of  3.5 
to 5.5% and dehydroepiandrosterone sulfate (DHEAS) 
values with inter- and intra-assay CVs of  4.4 to 6.4% 
were determined using Elisa kits (DiaMetra, Milano, 
Italy). Free androgen index (FAI) was calculated as the 
ratio of  total testosterone to SHBG. Serum hs-CRP 
levels were assessed by an ELISA kit (LDN, Nordhorn, 
Germany) with inter- and intra-assay CVs of  4.9 to 6.8%, 
respectively. The plasma NO using Griess method,19 total 
antioxidant capacity (TAC) by the use of  ferric reducing 
antioxidant power developed by Benzie and Strain,20 total 
glutathione (GSH) using the method of  Beutler et al.21 
and malondialdehyde (MDA) values by the thiobarbituric 
acid reactive substances spectrophotometric test22 were 
determined with inter- and intra-assay CVs less than 5%. 
Sample Zize
Using a formula suggested for clinical trials, having 25 
subjects in each group were adequate while considering 
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a type one error (α) of  0.05 and type 2 error (β) of  0.20 
(power = 80%), 441.7 ng/mL as SD and 335.0 ng/mL as 
the mean distinction (d) of  hs-CRP as the main outcome.23 
The correlation of  hs-CRP between subsequent 8-week 
periods was r = 0.29. Assuming 5 dropouts in each group, 
the final sample size was determined to be 30 subjects in 
each group. 
Randomization
Randomization assignment was performed using 
computer-generated random numbers. Randomization 
and allocation were concealed from the investigators and 
participants until the final analyses were completed. The 
randomized allocation sequence, enrolling participants 
and allocating them to interventions were conducted by 
a trained staff  at the clinic. Another person, who was not 
involved in the trial and not aware of  random sequences, 
assigned the subjects to the numbered bottles of  capsules.
Statistical Methods
To evaluate whether the study variables were normally 
distributed or not, we used the Kolmogrov-Smirnov 
test. The Pearson chi-square test was used to compare 
categorical variables. To detect differences in 
anthropometric measures and in macro- and micro-
nutrient intakes between the 2 groups, we applied 
independent t test. To assess the effects of  probiotic 
supplementation on hormonal profiles, biomarkers of 
inflammation and oxidative stress, we used one-way 
repeated measures analysis of  variance. Adjustment for 
changes in baseline values of  biochemical parameters 
was performed by analysis of  covariance (ANCOVA) 
using general linear models. The P value of  <0.05 were 
considered statistically significant. All statistical analyses 
used the Statistical Package for Social Science version 18 
(SPSS Inc., Chicago, Illinois, USA).
Results
Firstly, we invited 71 participants with PCOS; however, 11 
subjects were excluded in the eligibility phase because of 
not meeting inclusion criteria. All 60 subjects (probiotic 
[n = 30] and placebo [n = 30]) completed the trial (Figure 
1). On average, the rate of  compliance ranged between 
90% to 100% both groups. No side effects were reported 
following the consumption of  probiotic supplements in 
subjects with PCOS throughout the study.
Mean age, height, and weight, body mass index (BMI) 
and METs at baseline and end-of-trial were not significant 
between the 2 groups (Table 1). After 12 weeks of 
intervention, the frequency of  decreased alopecia (15.8 
vs. 5.6%, P = 0.31) and acne (26.3 vs. 9.5 %, P = 0.16) 
did not change following the consumption of  probiotic 
supplements compared with the placebo. 
No significant difference in mean dietary macro- 
and micro-nutrient intakes between the 2 groups was 
observed (Data not shown).
After a 12-week intervention, compared with the 
placebo, probiotic supplementation significantly 
increased serum SHBG (+25.9 ± 32.5 vs. +0.5 ± 15.6 
nmol/L, P < 0.001) and plasma TAC (+8.8 ± 120.5 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Summary of patient flow diagram. 
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Figure 1. Summary of Patient Flow Diagram.
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vs. -98.3 ± 246.4 mmol/L, P = 0.04) and significantly 
decreased serum total testosterone (-0.2 ± 0.7 vs. +0.2 ± 
0.6 ng/mL, P = 0.03), mF-G scores (-1.7 ± 1.5 vs. -0.2 
± 1.0, P < 0.001), serum hs-CRP (-1150.0 ± 1295.2 vs. 
+202.5 ± 1426.3 ng/mL, P < 0.001) and plasma MDA 
concentrations (-0.2 ± 0.6 vs. +0.9 ± 1.3 µmol/L, P < 
0.001) (Table 2). We did observe no detrimental effect of 
probiotic supplementation on other metabolic profiles. 
Baseline levels of  serum testosterone levels (P < 
0.001) were significantly different between the 2 groups. 
Therefore, we controlled the analyses for the baseline 
levels. When we adjusted the analyses for baseline values 
of  biochemical variables, significant changes in plasma 
GSH levels (P = 0.001) were observed, but other findings 
did not alter (Table 3). 
Discussion
To the best of  our knowledge, this investigation is the 
first report of  probiotic supplementation on hormonal 
profiles, biomarkers of  inflammation and oxidative 
stress in women with PCOS. We found that taking 
probiotic supplements for 12 weeks by PCOS women 
had beneficial effects on total testosterone, SHBG, mFG 
scores, hs-CRP, TAC and MDA levels, but did not affect 
Table 1. General Characteristics of Study Participants
Placebo group
(n = 30)
Probiotic Group
(n = 30)
Pa
Age (y) 27.7 ± 4.7 27.2 ± 4.6 0.70
Height (cm) 164.5 ± 5.5 163.2 ± 6.0 0.36
Weight at study baseline (kg) 63.7 ± 8.0 62.9 ± 7.8 0.68
Weight at end-of-trial (kg) 63.8 ± 8.0 62.7 ± 7.8 0.57
BMI at study baseline (kg/m2) 23.6 ± 3.5 23.7 ± 3.6 0.91
BMI at end-of-trial (kg/m2) 23.6 ± 3.5 23.6 ± 3.6 0.98
Data are shown as mean ± SD. 
a Obtained from independent t test.
Table 2. Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress at Baseline and After the 12-Week Intervention in Subjects With Polycystic Ovary 
Syndrome
Placebo Group (n = 30) Probiotic Group (n = 30)
P a
Baseline End-of-Trial Change Baseline End-of-Trial Change 95% CI
Total testosterone 
(ng/mL)
1.9 ± 0.7 2.1 ± 0.8 0.2 ± 0.6 1.3 ± 0.7 1.1 ± 0.8 -0.2 ± 0.7 0.02, 0.7 0.03
SHBG (nmol/L) 52.5 ± 18.4 52.9 ± 16.2 0.5 ± 15.6 46.3 ± 10.3 72.2 ± 31.9 25.9 ± 32.5 -38.6, -12.2 <0.001
FAI 0.14 ± 0.07 0.15 ± 0.08 0.005 ± 0.06 0.09 ± 0.05 0.07 ± 0.09 -0.02 ± 0.09 -0.01, 0.07 0.16
mF-G scores 12.6 ± 4.5 12.4 ± 4.5 -0.2 ± 1.0 14.1 ± 4.9 12.4 ± 3.8 -1.7 ± 1.5 1.1, 2.3 <0.001
DHEAS (µg/mL) 1.3 ± 0.4 1.2 ± 0.5 -0.1 ± 0.3 1.1 ± 0.6 1.2 ± 0.7 0.07 ± 0.4 -0.3, 0.1 0.19
hs-CRP (ng/mL) 3281.9 ± 1983.5 3384.4 ± 2404.9 202.5 ± 1426.3 3546.7 ± 1003.1 2396.7 ± 1588.6 -1150.0 ± 1295.2 648.4, 2056.5 <0.001
NO  (μmol/L) 41.0 ± 8.8 39.3 ± 13.2 -1.6 ± 8.8 42.9 ±2.2 43.1 ± 1.8 0.2 ± 2.7 -5.2, 1.5 0.28
TAC (mmol/L) 904.6 ± 308.9 806.2 ± 339.3 -98.3 ± 246.4 935.5 ± 344.8 948.3 ± 380.2 8.8 ± 120.5 -207.4, -6.9 0.04
GSH (µmol/L) 456.7 ± 115.7 418.6 ± 129.1 -38.0 ± 154.9 494.6 ± 121.2 527.4 ± 98.1 32.8 ± 146.1 -148.7, 7.0 0.07
MDA (µmol/L) 2.3 ± 0.9 3.2 ± 1.1 0.9 ± 1.3 2.1 ± 0.4 1.9 ± 0.6 -0.2 ± 0.6 0.6, 1.7 <0.001
Abbreviations: DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; GSH, total glutathione; hs-CRP, high-sensitivity C-reactive protein; mF-G, 
modified Ferriman Gallwey; MDA, malondialdehyde; NO, nitric oxide; SHBG, sex hormone-binding globulin; TAC, total antioxidant.
All values are shown as mean ± SD. 
a P values represent independent t test.
other metabolic profiles. 
PCOS women are susceptible to multiple metabolic 
disturbances such as hyperandrogenemia, increased 
inflammation and oxidative stress.24,25 In addition, 
micronutrients deficieny is common in women 
childbearing age,26 which in turn may increase metabolic 
complications in women with PCOS. We found that 
probiotic administration for 12 weeks to PCOS women 
led to a significant increase in serum SHBG and a 
significant decrease in serum total testosterone and mFG 
scores but did not affect serum DHEAS levels compared 
with placebo. However, to the best of  our knowledge, 
data on the effects of  probiotic supplementation on 
hormonal profiles in women with PCOS are limited. 
Multiple studies have evaluated the effects of  probiotic 
supplementation on markers of  insulin resistance among 
subjects without PCOS. In a meta-analysis study, we 
have previously shown that synbiotic supplementation 
in patients with metabolic diseases to improve glucose 
homeostasis parameters was useful. In addition, some 
investigators indicated that taking probiotic supplements 
for 8 weeks by people with T2DM23 and patients with 
rheumatoid arthritis was beneficial in improving markers 
of  insulin metabolism, whereas other studies concluded 
that this approach had no detrimental effects among 
overweight men and women27 and healthy volunteers.28 
Probiotic intake might improve total testosterone, 
SHBG and mFG scores through improved insulin 
sensitivity, elevation of  fecal pH29 and reduction of  pro-
inflammatory cytokine production.30
Our study demonstrated that, compared with the 
placebo, taking probiotic supplements for 12 weeks 
by subjects with PCOS decreased serum hs-CRP and 
plasma MDA and increased plasma TAC but did not 
change plasma NO and GSH concentrations. In line 
with our study, in people with major depressive disorder, 
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probiotic supplementation for 8 weeks was effective in 
reducing serum hs-CRP concentrations.31 In addition, 
in critically-ill patients, administration of  probiotics 
was demonstrated to reduce cardiovascular risk factors 
such as hs-CRP.32 However, in another study, an 8-week 
probiotic supplementation had no beneficial effect on 
CRP levels in PCOS patients.33 Kullisaar et al34 observed 
that 2 Lactobacillus fermentum strains, E-3 and E-18, 
have antioxidative properties such as increased levels 
of  GSH. Moreover, Songisepp et al35 found significant 
improvement in total antioxidant status after probiotics 
supplementation for 3 weeks in healthy people. However, 
synbiotic supplementation for 6 weeks in subjects with a 
low serum enterolactone concentration did not influence 
serum CRP values.36 A previous investigation has 
reported that probiotic yogurt intake for 6 weeks could 
improve antioxidant status in people with T2DM.37 
Increased CRP concentrations are positively correlated 
with insulin resistance and the incidence of  T2DM.38 
Therefore, high CRP concentrations are considered a 
potential cause of  long-term consequences of  PCOS.39 
Toulis et al40 found that CRP levels were significantly 
increased in subjects with PCOS compared with controls. 
In addition, accumulating evidence has reported that 
increased oxidative stress induced by oxygen species (ROS) 
may contribute to the progress of  insulin resistance and 
hyperandrogenism which are main features of  PCOS.41 
It was also reported by multiple previous investigations, 
subjects with PCOS indicate reduction in antioxidant 
status and increased oxidative stress status,42 physiological 
concentrations of  ROS have an important function in 
female reproductive system during folliculogenesis and 
oocyte maturation.43 Therefore, to manage and control 
parameters of  inflammation and oxidative stress in 
PCOS women, these are important factors in decreasing 
events related to metabolic disorders. Anti-inflammatory 
and antioxidant effects of  probiotics may be explained 
by their production of  saturated fatty acids in the gut44 
and its impact on decreasing lipid peroxidation such as 
oxidized LDL and 8-isoprostanes.45
Strengths of  the present study include its double-
blinded design and consideration of  the confounding 
parameters including dietary nutrient intake and physical 
activity. Its limitations include absence of  fecal sample 
data to demonstrate transit of  the specific probiotic 
through the gastrointestinal tracts of  study subjects in 
the intervention group. 
Overall, probiotic supplementation for 12 weeks in 
PCOS women had beneficial effects on total testosterone, 
SHBG, mFG scores, hs-CRP, TAC and MDA levels, but 
did not affect other metabolic profiles.
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